CANF
Can-Fite BioPharma Ltd.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Sell
-31/100
Last price
2.23
▲ 0.09 (4.21%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.23
Prev close
2.14
Day high
2.14
Day low
2.11
Volume
23.80K
Market cap
$6.49M
P/E (TTM)
—
52W range
2.11 – 12.40
Day trading desk
Gap from prior close
+4.21%
Prior close 2.14
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
2.23 – 2.23
Position in range
—
—
ATR (14D)
0.06
2.88% of price
Prior day high
2.15
PDH
Prior day low
2.12
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 394.05K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.83%
-3.8%
1M
-4.04%
-5.2%
3M
-34.15%
-38.7%
6M
-29.37%
-47.6%
YTD
-46.50%
-60.7%
1Y
-82.74%
-99.2%
3Y
-95.96%
-178.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CANF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$6.49M
Enterprise value$-2.41M
Revenue (TTM)$405.00K
Gross profit$405.00K
EBITDA$-9.73M
Net income$-9.55M
EPS (TTM)$-13.23
Free cash flow$-5.58M
Total cash$7.04M
Total debt$49.00K
Book value / share$2.27
Shares outstanding3.03M
Float2.14M
Short % of float1.97%
Dividend yield0.00%
Beta (5Y)-0.02
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.35
PEG ratio—
Price / sales—
Price / book0.94
EV / revenue-5.95
EV / EBITDA0.25
Gross margin100.00%
Operating margin-2316.83%
Profit margin0.00%
Return on equity-211.37%
Return on assets-77.12%
Debt / equity1.01
Current ratio3.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $405.00K | $674.00K | $743.00K | $810.00K | — | -39.9% |
| Operating revenue | $405.00K | $674.00K | $743.00K | $810.00K | — | -39.9% |
| Research & development | $6.69M | $5.76M | $5.98M | $7.76M | — | +16.3% |
| Selling, general & admin | $3.66M | $3.05M | $2.96M | $3.14M | — | +20.2% |
| Total operating expense | $10.36M | $8.80M | $8.94M | $10.91M | — | +17.6% |
| Operating income | -$9.95M | -$8.13M | -$8.20M | -$10.10M | — | -22.4% |
| Net interest income | $270.00K | $277.00K | $492.00K | $206.00K | — | -2.5% |
| Pre-tax income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | — | -24.7% |
| Tax provision | — | — | $0 | $0 | $0 | — |
| Net income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | — | -24.7% |
| Net income to common | -$9.83M | -$7.88M | -$7.63M | -$10.17M | — | -24.7% |
| Basic EPS | -10.75 | -19.55 | -32.26 | -60.00 | — | +45.0% |
| Diluted EPS | -10.75 | -19.55 | -32.26 | -60.00 | — | +45.0% |
| EBIT | -$9.95M | -$8.13M | -$8.20M | -$10.10M | — | -22.4% |
| EBITDA | -$9.93M | -$8.12M | -$8.18M | -$10.08M | — | -22.2% |
| Basic shares | 914.56K | 402.95K | 236.73K | 135.96K | — | +127.0% |
| Diluted shares | 914.56K | 402.95K | 236.73K | 135.96K | — | +127.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.53M | $4.83M | $4.28M | $2.98M | +14.6% |
| Cash & short-term investments | $8.54M | $7.89M | $8.92M | $7.99M | +8.3% |
| Total current assets | $9.44M | $8.98M | $9.91M | $9.16M | +5.1% |
| Property, plant & equipment | $74.00K | $138.00K | $81.00K | $126.00K | -46.4% |
| Total assets | $9.51M | $9.12M | $9.99M | $9.28M | +4.3% |
| Total current liabilities | $2.73M | $2.05M | $2.02M | $2.50M | +33.1% |
| Total debt | $71.00K | $104.00K | $40.00K | $62.00K | -31.7% |
| Total liabilities | $3.92M | $3.68M | $3.75M | $4.81M | +6.5% |
| Retained earnings | -$176.19M | -$166.36M | -$158.48M | -$150.85M | -5.9% |
| Shareholder equity | $5.59M | $5.44M | $6.24M | $4.47M | +2.9% |
| Working capital | $6.71M | $6.93M | $7.89M | $6.66M | -3.2% |
| Net tangible assets | $5.59M | $5.44M | $6.24M | $4.47M | +2.9% |
| Shares issued | 2.62M | 994.39K | 453.28K | 271.92K | +163.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | -24.7% |
| Depreciation & amortisation | $24.00K | $7.00K | $15.00K | $14.00K | +242.9% |
| Stock-based compensation | $340.00K | $362.00K | $261.00K | $263.00K | -6.1% |
| Change in working capital | $433.00K | -$267.00K | -$943.00K | -$1.30M | +262.2% |
| Operating cash flow | -$8.95M | -$7.64M | -$8.44M | -$10.80M | -17.2% |
| Capital expenditure | -$2.00K | -$5.00K | -$2.00K | -$9.00K | +60.0% |
| Investing cash flow | -$2.00K | $1.50M | $498.00K | $9.50M | -100.1% |
| Financing cash flow | $9.64M | $6.71M | $9.14M | $0 | +43.7% |
| Free cash flow | -$8.95M | -$7.64M | -$8.44M | -$10.81M | -17.1% |
| End cash position | $5.53M | $4.83M | $4.28M | $2.98M | +14.6% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $5.53M | — | — |
| Cash & short-term investments | $8.54M | $6.46M | +32.3% |
| Total current assets | $9.44M | $7.62M | +23.8% |
| Property, plant & equipment | $74.00K | — | — |
| Total assets | $9.51M | — | — |
| Total current liabilities | $2.73M | — | — |
| Total debt | $71.00K | — | — |
| Total liabilities | $3.92M | $3.54M | +10.9% |
| Retained earnings | -$176.19M | — | — |
| Shareholder equity | $5.59M | $4.18M | +33.7% |
| Working capital | $6.71M | $5.50M | +21.9% |
| Net tangible assets | $5.59M | — | — |
| Shares issued | 2.62M | 1.32M | +98.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | -2.80 | — | — |
| Sep 2025 | -2.80 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | -2.04 | 1 | $404.00K | -0.3% |
| Next year | -0.91 | 1 | $404.00K | 0.0% |
Analyst targets & ownership
Mean target$8.00
High target$8.00
Low target$8.00
Implied upside258.74%
Analyst count1
ConsensusSTRONG BUY
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions1.66%
Institutions holding9
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.18
+2.43% from price
SMA 20
2.21
-3.08% from price
SMA 50
2.80
-23.53% from price
SMA 100
3.02
-26.06% from price
SMA 200
3.43
-37.59% from price
EMA 12
2.21
+1.10% from price
EMA 26
2.38
-6.33% from price
EMA 50
2.64
-15.39% from price
RSI (14)
32.0
Neutral
MACD (12,26,9)
-0.18
Hist 0.03
ATR (14)
0.06
3.00% of price
Realised vol 30D
102.6%
Annualised
Bollinger upper
2.31
20, 2σ
Bollinger lower
2.11
20, 2σ
50 / 200 cross
Death
2.80 vs 3.43
Trend bias
Below 200
-37.59%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.74
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
102.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-82.7%
Peak to trough
Max drawdown 5Y
-99.5%
Peak to trough
ATR 14
0.06
3.00% of price
Beta (reported)
-0.02
5Y monthly, from filing
Short interest
Shares short
59.38K
Prior 61.81K
Change vs prior
-3.9%
Shorts covering
% of float
1.97%
Normal
% of shares out
1.96%
Against total outstanding
Days to cover
0.1
Liquid
Float
2.14M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 26 | D. Boral Capital | UPGRADE | Hold | Buy |
| May 12, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 24, 25 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Dec 17, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 18, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 16, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 2, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 29, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Apr 15, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 21, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 20, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateMay 10, 2019
Last split1:20
Split dateJan 5, 2026
SEC filings
Offering Registrations
F-3 · 2026-09-25
Additional Forms
D · 2026-09-10
Corporate Changes & Voting Matters
6-K · 2026-09-09
Post-effective amendment to a registration statement that is not immediately effective upon filing
POS AM · 2026-09-08
Corporate Changes & Voting Matters
6-K · 2026-09-03
Corporate Changes & Voting Matters
6-K · 2026-09-02
Offering Registrations
F-3 · 2026-08-28
Corporate Changes & Voting Matters
6-K · 2026-08-17
Headlines
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
GlobeNewswire · 28d ago
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
GlobeNewswire · 29d ago
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
GlobeNewswire · 35d ago
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
GlobeNewswire · 35d ago
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
GlobeNewswire · 51d ago
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
GlobeNewswire · 56d ago
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
GlobeNewswire · 65d ago
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
GlobeNewswire · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.